Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo-controlled trial (Q47357954)

From Wikidata

Jump to navigation Jump to search

scientific article published in March 1995

Language	Label	Description	Also known as
English	Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo-controlled trial	scientific article published in March 1995

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/7869205

Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/7869205

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Ohls RK

1

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/7869205

Osborne KA

2

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/7869205

Christensen RD

3

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/7869205

language of work or name

0 references

publication date

1 March 1995

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/7869205

The Journal of Pediatrics

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/7869205

126

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/7869205

3

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/7869205

421-426

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/7869205

Erythropoietin and neonatal anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970462-0

7 January 2021

The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970462-0

7 January 2021

Recombinant human erythropoietin vs transfusions in the treatment of anemia of prematurity. A cost-benefit analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970462-0

7 January 2021

A randomized, double-blind, placebo-controlled trial of recombinant erythropoietin in treatment of the anemia of bronchopulmonary dysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970462-0

7 January 2021

Portal Venous and Aortic Glucose and Lactate Changes in a Chronically Catheterized Rat

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970462-0

7 January 2021

Relationship between determinants of oxygen delivery and respiratory abnormalities in preterm infants with anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970462-0

7 January 2021

Anemia of prematurity: determinants of the erythropoietin response

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970462-0

7 January 2021

Decreased response of plasma immunoreactive erythropoietin to "available oxygen" in anemia of prematurity

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970462-0

7 January 2021

Recombinant erythropoietin compared with erythrocyte transfusion in the treatment of anemia of prematurity

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970462-0

7 January 2021

Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970462-0

7 January 2021

Sepsis associated with transfusion of red cells contaminated with Yersinia enterocolitica

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970462-0

7 January 2021

Direct evidence for erythropoietin-induced release of endothelin from peripheral vascular tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970462-0

7 January 2021

BQ123, an ETA Receptor Antagonist, Attenuates Endothelin-1-Induced Vasoconstriction in Rat Pulmonary Circulation

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970462-0

7 January 2021

Erythropoietin affects the maturation pattern of fetal G-CSF-responsive progenitors

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970462-0

7 January 2021

Identifiers

10.1016/S0022-3476(95)70462-0

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/7869205

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/7869205

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47357954&oldid=2153340614"